(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Xenon Pharmaceuticals's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast XENE's revenue for 2026 to be $401,258,698, with the lowest XENE revenue forecast at $0, and the highest XENE revenue forecast at $2,537,470,688. On average, 21 Wall Street analysts forecast XENE's revenue for 2027 to be $10,418,612,979, with the lowest XENE revenue forecast at $1,326,734,674, and the highest XENE revenue forecast at $42,680,740,292.
In 2028, XENE is forecast to generate $29,449,159,808 in revenue, with the lowest revenue forecast at $11,908,229,105 and the highest revenue forecast at $85,868,008,065.